Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer

  • Manabu Hoshi
  • Masatsugu Takami
  • Makoto Ieguchi
  • Kunio Takaoka
Case Report

DOI: 10.1007/s00590-008-0406-6

Cite this article as:
Hoshi, M., Takami, M., Ieguchi, M. et al. Eur J Orthop Surg Traumatol (2009) 19: 181. doi:10.1007/s00590-008-0406-6

Abstract

We present a 67-year-old woman with advanced-stage lung adenocarcinoma (T2N3M1, Stage IV). Palliative surgery with an intramedullary nail was performed for the sudden onset of a pathological fracture of the right proximal femur. Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, administration without radiotherapy for 3 months led to remarkable recovery of the mineralization in the metastatic femoral lesion, in accordance with size reduction of the primary lung tumor. Her serum CEA level markedly decreased. She has remained alive during follow-up for 22 months after the surgery, and has suffered no adverse effects of gefitinib administration other than a skin rash and mild diarrhea. Oral gefitinib administration had an excellent effect on bone repair and mineralization for a pathological fracture of metastatic lung adenocarcinoma.

Keywords

Pathological fracture Lung cancer Gefitinib Bone metastasis 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Manabu Hoshi
    • 1
  • Masatsugu Takami
    • 2
  • Makoto Ieguchi
    • 1
  • Kunio Takaoka
    • 1
  1. 1.Department of Orthopedic SurgeryOsaka City University Graduate School of MedicineAbeno-KuJapan
  2. 2.Department of Orthopedic SurgeryYodogawa Christian HospitalHigashi-yodogawa-kuJapan

Personalised recommendations